Aldevron announces cancer vaccine manufacturing agreement with CureLab Oncology

Aldevron announces cancer vaccine manufacturing agreement with CureLab Oncology
CureLab Oncology selects Aldevron to produce DNA-based vaccine for cancer treatment

December 4, 2012. Aldevron (Fargo, ND) has entered into an agreement to produce CureLab Oncology's proprietary DNA-based vaccine for the treatment of cancer. The vaccine has demonstrated strong antitumor responses in animal models of lung carcinoma and breast cancer. The effect manifested both as growth inhibition for the primary tumors as well as reduction of the number of metastases. The immunological memory provided by vaccination has lasted in animal models for two years.

The vaccine product is a multicenter project conducted in partnerships with the University of Camerino (Italy), Medical Radiological Research Center, RAMS (Russia), National Institute of Influenza (Russia), R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (Ukraine) and Boston University (USA).   "We have conducted a comprehensive worldwide search for plasmid manufacturing," said Alex Shneider, Ph.D., Founder and CEO of CureLab Oncology. "We have selected Aldevron for three main reasons: great quality, proven international experience and talent to work with the different corporate cultures of their clients."   According to Aldevron CEO Michael Chambers, "Dr. Shneider and his team at CureLab Oncology are well known for their DNA vaccine expertise. It is an honor to manufacture DNA for them." Chambers noted that Aldevron's high quality specifications have been demonstrated to meet regulatory standards for both US and international clinical oncology applications. Under the contract, Aldevron will supply material for CureLab Oncology's clinical trials in both Russia and the United States. "It is our hope that Cure Lab's technology will help many people suffering from cancer," said Chambers.   About Aldevron Aldevron provides plasmid DNA manufacturing services for research, clinical, diagnostic, and commercial applications. The Company has been recognized for producing the world's first DNA vaccine to be used outside of a trial setting. The company also produces recombinant proteins and offers a proprietary antibody development technology that is based on genetic immunization. The company consistently ranks among the best places to work in The Scientist's annual survey and has global operations with offices in the US and Europe. For more information visit

About Cure Lab
CureLab Oncology, Inc. is a subsidiary of Cure Lab, Inc. The company mission is to treat and prevent cancer through novel DNA vaccines and virotherapy. In addition to its American operations, CureLab Oncology also has a subsidiary in Russia, OOO CL Oncology, which received funding from the Russian government program Pharma 2020 and a special Skolkovo status. In 2013, CureLab Oncology, Inc. is planning to relocate the majority of their US operations to their branch in Fargo, North Dakota. For more information, visit

Media Contact: Michael Chambers • Aldevron
(701) 297-9256 • [email protected]